Inventor
ASSENMACHER MARIO
DE16 patents
⚠️ This page may combine multiple inventors who share the name “ASSENMACHER MARIO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MILTENYI BIOTEC GMBH
9 patentsUS11033619B2Jun 15, 2021
Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form
MILTENYI BIOTEC GMBH15 citations93
US10201606B2Feb 12, 2019
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
MILTENYI BIOTEC GMBH18 citations93
US10131876B2Nov 20, 2018
Method for automated generation of genetically modified T cells
MILTENYI BIOTEC GMBH49 citations92
US6468432B1Oct 22, 2002
Methods of modification of selected cells in a magnetic cell separation column
MILTENYI BIOTEC GMBH19 citations92
US11890300B2Feb 6, 2024
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
MILTENYI BIOTEC GMBH3 citations69
US10513687B2Dec 24, 2019
Method for polyclonal stimulation of T cells by flexible nanomatrices
MILTENYI BIOTEC GMBH1 citations60
US10871490B2Dec 22, 2020
Assay for detection of chimeric antigen receptor T cells
MILTENYI BIOTEC GMBH1 citations57
US10890580B2Jan 12, 2021
Reversible cell labelling with conjugates having two releasable binding sites
MILTENYI BIOTEC GMBH0 citations43
US9638689B2May 2, 2017
Indirect antigen-specific T cell recognition assay
MILTENYI BIOTEC GMBH0 citations36
MILTENYI BIOTEC BV & CO KG
6 patentsUS11419935B2Aug 23, 2022
Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells
MILTENYI BIOTEC BV & CO KG5 citations82
US12246065B2Mar 11, 2025
Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen
MILTENYI BIOTEC BV & CO KG1 citations73
US11883494B2Jan 30, 2024
Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form
MILTENYI BIOTEC BV & CO KG2 citations71
US12576148B2Mar 17, 2026
Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens
MILTENYI BIOTEC BV & CO KG0 citations61
US12521434B2Jan 13, 2026
Hematopoietic cells with a modified CD antigen for reducing side effects of cancer immunotherapy
MILTENYI BIOTEC BV & CO KG0 citations61
US12318446B2Jun 3, 2025
Reducing side effects of immunotherapy using genetically modified hematopoietic cells
MILTENYI BIOTEC BV & CO KG0 citations61